Have you or someone you know been diagnosed with persistent or chronic ITP?

Are you struggling with ITP?


The Study

  • A study evaluating the safety of oral Rilazbrutinib in adolescents and adults with ITP.

Study Benefits

  • This medication has been seen to reduce the destruction of platelets and also reduce the impairment of platelet production
  • First oral medication of its kind to treat refractory or relapsed ITP

Study Volunteers Must Meet the Following Criteria

  • Males and females
  • Ages 18 and above with ITP of greater than 3 months in duration
  • Aages 12-18 with ITP of greater than 6 months in duration

Study Participant Expectations

  • 60-week study duration
  • 12 to 14 weeks of blinded study treatment
  • 28 weeks of open label medication administration
  • 4 weeks of post-dose follow up
  • 12-month long term extension study available


  • There is no cost to participate.
  • Patients who qualify may be compensated for time and travel